What is the recommended treatment for Enterococcus faecalis infections?

Treatment of Enterococcus faecalis Infections

For susceptible Enterococcus faecalis infections, ampicillin or amoxicillin remains the drug of choice, with specific regimens varying by infection site and severity.

Infection Site-Specific Treatment Approach

Uncomplicated Urinary Tract Infections

• Ampicillin (18-30 g IV daily in divided doses) or amoxicillin (500 mg PO/IV every 8 hours) is recommended 1
• High urinary concentrations can overcome elevated ampicillin MICs, achieving bactericidal activity even in ampicillin-resistant strains 1
• Alternative oral agents include:
  • Fosfomycin 3 g PO single dose 1
  • Nitrofurantoin 100 mg PO every 6 hours 1
• Clinical and microbiological eradication rates of 88.1% and 86% respectively have been reported with ampicillin for UTIs, even with ampicillin-resistant VRE 1

Bloodstream Infections (Uncomplicated)

• Aminopenicillins (ampicillin or amoxicillin) are first-line therapy 2, 3
• Oral switch therapy with aminopenicillins after initial IV treatment is effective and safe, reducing hospital length of stay from 11 to 7 days without increasing treatment failure risk (hazard ratio 0.77) 2
• For severe infections, combine aminopenicillins with gentamicin for synergistic bactericidal activity 3, 4

Infective Endocarditis

• Ampicillin plus gentamicin combination has been the traditional cornerstone, though high-level aminoglycoside resistance has necessitated alternatives 5
• Dual beta-lactam therapy with ampicillin plus ceftobiprole shows promise, with 81% clinical success and 86% microbiological cure rates 6
• Treatment duration: 6-8 weeks to prevent relapses 5
• Therapeutic drug monitoring (TDM) should be performed to optimize ampicillin and ceftobiprole concentrations relative to MICs 6

Intra-abdominal Infections

Mild to Moderate Severity:

• Amoxicillin-clavulanic acid as first-line monotherapy 1
• Alternative: Ampicillin + gentamicin + metronidazole (particularly in children) 1
• Second-line options: Ciprofloxacin + metronidazole OR cefotaxime/ceftriaxone + metronidazole 1

Severe Infections:

• Cefotaxime or ceftriaxone + metronidazole as first choice 1
• Add ampicillin if the regimen lacks enterococcal coverage (e.g., ceftriaxone-metronidazole combination) 1
• Alternative: Piperacillin-tazobactam or meropenem 1

Vancomycin-Resistant E. faecalis (VRE)

General Principles

• VRE rates vary significantly: E. faecalis shows 7.2% vancomycin non-susceptibility versus 82.1% for E. faecium 1
• Differentiate colonization from true infection before initiating anti-VRE therapy 1

Treatment Options by Site

Systemic/Bacteremia:

• Linezolid 600 mg IV or PO every 12 hours (strong recommendation) 1
• High-dose daptomycin 8-12 mg/kg/day, preferably combined with beta-lactams (penicillins, cephalosporins, or carbapenems) for bacteremia 1
• High-dose daptomycin-beta-lactam combinations show 77% mortality reduction and better survival compared to monotherapy (adjusted HR 19.01 for high-dose combination) 1

Intra-abdominal Infections:

• Tigecycline 100 mg IV loading dose, then 50 mg IV every 12 hours 1
• Tigecycline achieves high peritoneal penetration with 97.6% overall success rates in VRE infections 1
• Avoid tigecycline for bacteremia due to large volume of distribution and low serum levels 1

Urinary Tract Infections:

• Same options as susceptible strains: ampicillin, fosfomycin, or nitrofurantoin 1

Critical Pitfalls and Caveats

Resistance Considerations

• E. faecalis demonstrates very low resistance to aminopenicillins globally 3, 7
• Daptomycin and tigecycline remain highly effective with low resistance rates worldwide 7
• Avoid cephalosporin monotherapy—E. faecalis has intrinsic low-affinity penicillin-binding proteins causing partial resistance 5, 4

Combination Therapy Nuances

• Daptomycin MIC 3-4 mg/mL predicts treatment failure (OR 3.23) unless combined with beta-lactams 1
• Daptomycin-cefotaxime or daptomycin-cefazolin combinations lack synergy against VRE 1
• Aminoglycoside combinations require checking for high-level resistance before use 5

Emerging Options

• Ampicillin-ceftobiprole combination achieves high enterococcal PBP saturation and is well-tolerated 6
• Long-acting lipoglycopeptides (dalbavancin, oritavancin) are under investigation for outpatient parenteral therapy 5